

SCRI Trials and Trial Regimen Updates

The following updates were completed between Sept. 20, 2024, through Oct. 18, 2024. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAlysts@scri.com.

New Builds Completed

Study Number	Notes for New Build
23300	USOR 23300 GI 368 Phase I TORL-2-307-ADC Q21D
23182	<p>USOR 23182 AML 72 Phase 1 Consolidation Ziftomenib + (HiDAC) Cytarabine Q28D</p> <p>USOR 23182 AML 72 Phase 1 Consolidation Ziftomenib + (IDAC) Cytarabine Q28D</p> <p>USOR 23182 AML 72 Phase 1 Induction Ziftomenib + (FLAG-IDA) Fludarabine D1-4 + Cytarabine D1-5 + G-CSF D-1-5 + Idarubicin D1,3 Q28D</p> <p>USOR 23182 AML 72 Phase 1 Maintenance Ziftomenib Q28D</p> <p>USOR 23182 AML 72 Phase 1 Ziftomenib + (LDAC) Cytarabine Q28D</p> <p>USOR 23182 AML 72 Phase 1 Ziftomenib + Gilteritinib Q28D</p>
24249	USOR 24249 PRO 37 Extended Access Nab-Sirolimus IV D1,8 (+/- Letrozole PO) Q21D
23307	<p>USOR 23307 GI 370 Phase 1b Arm B AMG 193 + mFOLFIRINOX Q28D</p> <p>USOR 23307 GI 370 Phase 1b Part 1 Arm A bAMG 193 + nab-Paclitaxel (D1,8,15) + Gemcitabine (D1,8,15) Q28D</p> <p>USOR 23307 GI 370 Phase 1b Part 1 BTC AMG 193 + Pembrolizumab + Gemcitabine + Cisplatin D 1, 8 Q21D</p>
23276	USOR 23276 LUN 547 Phase III Tarlatamab or Placebo D1,8,15 fb D1,15 Q28D

Study Number	Notes for New Build
23297	USOR 23297 LUN 549 Phase 1b Subprotocol A Part 1 Arm A AMG 193 + Carboplatin + Paclitaxel + Pembrolizumab Q21D USOR 23297 LUN 549 Phase 1b Subprotocol A Part 1 Arm B AMG 193 + Carboplatin + Pemetrexed + Pembrolizumab Q21D USOR 23297 LUN 549 Phase 1b Subprotocol A Part 1 Arm C AMG 193 + Pembrolizumab Q21D USOR 23297 LUN 549 Phase 1b Subprotocol B Part 1 AMG 193 + Sotorasib Q21D USOR 23297 LUN 549 Phase 1b Subprotocol C Part 1 AMG 193 Q21D
24073	USOR 24073 MM185 Phase 3 Arm A Teclistamab SQ Cycle 1 Step Up Dosing USOR 24073 MM185 Phase 3 Arm A Teclistamab SQ Q28D Cycle 2+ USOR 24073 MM185 Phase 3 Arm B Carfilzomib D1,8,15 + Dexamethasone D1,8,15,22 fb D1,8,15 Q28D USOR 24073 MM185 Phase 3 Arm B Carfilzomib D1,2,8,9,15,16 + Dexamethasone D1,2,8,9,15,16,22,23 Q28D USOR 24073 MM185 Phase 3 Arm B Pomalidomide D1-14 + Bortezomib D1,4,8,11 fb D1,8 + Dexamethasone Q21D
24065	USOR 24065 CNS 37 Phase 2 BPM31510 IV + Vitamin K1 SC + Temozolomide PO qd + XRT Q7D USOR 24065 CNS 37 Phase 2 Additional Temozolomide Q28D

Updated Reference Information

Study Number	Updated Reference Information	Other Changes
23116	Pharmacy Manual V6	<ul style="list-style-type: none"> • Atezolizumab stability • Bevacizumab stability and dose changes

Study Number	Updated Reference Information	Other Changes
23078	RM930_Protocol_Amendment_v4_20240701_Clean	NA
20345	XPORT-MF-034 Protocol v5.0-29JUL2024 -	NA
23116	Protocol - ML44719 - AVASTIN - v5 - Published	NA
23229	TTX-030-003 IMP Pharmacy Manual_V2.0	NA
23141	EFC17757_Prednisone tapering_Memo_1_Final v2.0_29Aug2024	New prednisone tapering guidelines added
21550	CABL001AUS08--v02-protocol CABL001AUS08--v02tc-protocol	NA
24077	KT-US-484-0136 ZUMA 23 (A-1181-0036) Protocol Amendment 3 Memo	NA
23116	ML44719 Pharmacy Manual V6.0_Final Clean_10Jul2024.docx	NA
23066	Pharmacy Manual_1.0_08 Mar 2023 (2)	NA
23235	Pharmacy manual Protocol Version 3.0 (06AUG2024)	NA
21253	acr-368-201-protocol-v8-5june2024-final-	NA
22311	Tissue 32 CSP Amd 5 V6.1 Administrative Amendment 12Aug24-Final	NA
22302	STRO-002-GM3_PCL_- _Dose_Reductions_- _10Sep2024.docx	New doses added to regimes

Study Number	Updated Reference Information	Other Changes
22124	BMT54_Protocol_20240904_A0 6	NA